A Phase 4 interventional study of Ziprasidone and Olanzapine in Schizophrenia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 7 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing ziprasidone in Schizophrenia — none open to participants now, 1 under way, none of them phase 3. ziprasidone · Schizophrenia.
Among the 52 studies testing ziprasidone in Schizophrenia, this one is the 26th largest by enrollment, is one of 14 that started in 2003, is one of 26 in phase 4, and was the 14th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 52 studies testing ziprasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
ziprasidone: first FDA approval 2001 (GEODON). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 16 · Phase 4 26
First in 2000; this study’s year is marked. 14 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 106 across the 52 interventional studies. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
29 studies in Schizophrenia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 11 (38%) have results posted.
Among the 29 studies in Schizophrenia by Viatris Inc., this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2003, is one of 9 in phase 4, and was the 9th registered.
Viatris Inc.’s Schizophrenia studies by the year they started, since 2001.
1 of the studies testing ziprasidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 52 studies testing ziprasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 29 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To estimate and compare the effects of ziprasidone vs olanzapine on body weight in the treatment of patients with schizophrenia.
PANSS total score; change from baseline CGI severity; change from baseline CGI - Improvement PANSS negative subscale score; change from baseline DSM IV axis V Patient preference scale (PPS) Heath Utility Index Mark III BMI , Qaist Index
The record gives a start of Apr 2003 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ziprasidone · Olanzapine
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →